Post Graduate Award in Pharmacovigilance

• Flexible study concept with self-study and live webinars
• Certificate with exam and 10 ECTS

Pharmacovigilance covers the safety and risk issues one must address to ensure patients receive safe drugs. This course will give students a working knowledge of all aspects of drug safety monitoring and risk management, enable them to predict and analyse drug interactions and recognise the implications for prescribing and product license. The student will also be familiar with pharmacovigilance best practice, including monitoring strategies and action plans, and will be fully cognizant of regulatory reporting requirements.

After successfully completing this course, students will be able to:

Understand and critically appraise the principles of pharmacovigilance and landmark cases effecting change to recent drug safety issueExplain key operational drug safety definitionsDemonstrate good pharmacovigilance practice and locate key sources of information and documentationComprehend and discuss global pharmacovigilance Understand drug development and discuss the risks and safety assessment Critically explain the strengths and weakness of pharmacovigilance reporting systemsfuture challenges in drug safety and pharmacovigilance

Learning Aims and Objectives

The aim of this course is to provide education in pharmacovigilance and drug safety and includes  the history and their regulations and guidelines, the key components of the adverse event reporting in the clinical and postmarketing setting, reference safety information documentation, aggregated safety reports and an overview of signal detection and risk management processes.

The key learning objectives are: 

• Drug safety/pharmacovigilance (PV) regulations and practice, and sources of regulatory guidance
• Pharmacovigilance processes in the premarketing and postmarketing settings
• Adverse drug reactions, and process of individual case safety reporting (ICSR), including medical review, case narrative writing, causality assessment and expedited reporting
• Concept of reference safety information documents and its relevance
• Aggregated safety reports in the premarketing setting (Development Safety Update Reports- DSUR) and postmarketing setting (Periodic Benefit Risk Evaluation-PBREs).
• Signal detection processes including signal validation, prioritisation, evaluation, and recommendations
• Significance of risk management plan, presentation of the report template and its completion

Format & Content

Format:

The course is delivered in 12 weeks over a period of 3 months.

The course is a blended programme of study using a combination of teaching methods which includes:

Webinars (30 hours)

E-learning (12 hours)

Self-directed learning and reflective practice (268 hours)

The hours are an estimate of the time distribution and may vary in between weeks.

Content:

Week 1: Introduction of Pharmacovigilance
Aims:
The aims of this Week are to:
-    Explain the concept of pharmacovigilance (PV), the rationale for modern drug safety/pharmacovigilance (PV) regulation and practice
-    Describe the international policy-making bodies and sources of regulatory guidance
Learning Outcomes:
At the end of the participants will be able to:
-    Understand the concept of pharmacovigilance and drug safety, scope and history
-    Become familiar with the regulatory guidelines and laws that govern pharmacovigilance

Week 2: Drug Development Process
Aims:
The aims of this Week are to:
-    Provide an overview of the drug development process from preclinical drug trials to human clinical trials and the role of pharmacovigilance in the different stages
Learning Outcomes:
At the end of the Week the participants will be able to:
-    Become familiar with all stages of the drug development process from preclinical to clinical phases and the role of pharmacovigilance in the different stages

Week 3 The Principles of Pharmacovigilance
Aims:
The aims of this Week are to:
-    Describe all pharmacovigilance processes in premarketing and postmarketing setting, and areas of the pharmaceutical enterprise in which PV makes significant contributions
Learning Outcomes
At the end of the Week the participants will be able to:
-    Understand the pharmacovigilance function in the premarketing and post marketing settings and their differences

Week 4: Case Processing
Aims
The aims of this Week are to:
-    Describe the process of a single case, MedDRA coding of adverse events, and case narrative writing (single case and group narrative)
Learning Outcomes
At the end of the Week the participant will be able to:
-    Describe and understand the process of a single case report and how adverse events are coded 
-    Understand the importance of a case narrative and their challenges

Week 5: Reference Safety Information (RSI)
Aims
The aims of this Week are to:
-    Describe the reference safety information documents including the IB (Investigator Brochure) and the CDS (Core Data Sheet) and local labels.
-    Explain how expectedness is being assessed
-    Illustrate the importance of the RSI
Learning Outcomes
At the end of the Week the participant will be able to:
-    Become familiar with the concept of safety reference information, understand the different document types and when to make use of them
-    Understand the importance of the RSI in the pharmacovigilance context

Week 6:  Adverse Drug Reactions
Aims
The aims of this Week are to:
-    Define adverse drug reactions and individual case safety report, medical review, causality assessment and expedited reporting
-    Explain the difference between adverse drug event v adverse drug reaction
Learning Outcomes
At the end of the Week the participant will be able to:
-    Understand the concept of drug adverse reaction and apply rules to safety reporting (single case reports) based on theory and practical examples 
-    Understand the difference between adverse drug event v adverse drug reaction

Week 7: Aggregated Safety Reports I
Aims
The aims of this Week are to:
-    Provide an overview of the Developmental Safety Update Report (DSUR), aim and objectives, presentation of the report template and their completion
Learning Outcomes
At the end of the Week the participant will be able to:
-    Understand and become familiar with the concept of DSUR (aggregated safety report), its purpose and content 

Week 8: Aggregated Safety Reports II
Aims
The aims of this Week are to:
-    Provide an overview of the Periodic Benefit-Risk Evaluation Report (PBRER), aim and objectives, presentation of the report template and their completion
Learning Outcomes
At the end of the Week the participant will be able to:
-    Understand and become familiar with the concept of PBRE (aggregated safety reports), its purpose and content
 

Week 9:  Signal Management Process I
Aims
The aims of this Week are to:
-    Provide an overview of all activities related to the signal detection activity, including signal validation, prioritisation, evaluation, and recommendations
-    Tracking and documentation of signal detection activities.
Learning Outcomes
At the end of the Week the participant will be able to:
-    Describe all signal detection activities from identification of a signal to evaluation and final recommendations
-    Determine whether a signal represents a risk which may warrant further assessment, communication, or other risk minimization actions in accordance with the medical importance of the issues

Week 10:  Signal Management Process II
Aims
The aims of this Week are to:
-    Discuss practical examples of signal management.
-    Document a signal investigation as a drug safety report
Learning Outcomes
At the end of the Week the participant will be able to:
-    Understand the signal detection process from a practical example, and the concept of drug safety report as a documentation tool

Week 11:  Risk Management Plan (RMP)
Aims
The aims of this Week are to:
-    Provide an overview of the risk management plan aims and goals, presentation of the report template and its completion. 
-    Provide an understanding on how important risks of therapeutic drugs are to be minimized and/or further characterized
Learning Outcomes
At the end of the Week the participant will be able to:
-    Understand and become familiar with the concept of risk management plan, how to produce and update one, and which planning steps should be taken and why

Week 12: The Big Picture
Aims and Learning Outcomes
-    Review key points of pharmacovigilance, and conclusion.
Quiz and feedback
 

Learning Outcomes

• On successful completion of this course a student will be expected to be able to:
• Understand the basic aspects of pharmacovigilance and drug safety, scope and history, and the regulatory guidelines and laws that govern them.
• Understand the pharmacovigilance function in the premarketing and post marketing settings and their differences.
• Describe and understand the concept of adverse drug reaction, the process of a single case report, and how adverse events are coded.
• Become familiar with the concept of safety reference information, understand the different document types and when to make use of them. 
• Describe the signal detection process from identification of a signal to signal evaluation and final recommendations.
• Carry out a signal detection analysis from a practical example and understand the concept of a drug safety report as a documentation tool.
• Demonstrate an understanding of aggregated drug safety reports including DSURs (Development Safety Update Reports) and PBREs (Periodic Benefit Risk Evaluation).
• Become familiar with the concept of RMP (risk management plan), the report template and the content.

Schedule of the live webinars

All live webinars will be recorded and can be viewed again at any time and as often as you like. So if you have missed one of the webinars it is no problem. If you have any questions you can contact the speaker or simply ask your questions in the next live webinar.

Your benefits of the live webinars
✔ Flexible
✔ Location independent
✔ Participate live or watch the webinar later at your own leisure
✔ Ask your questions directly to the speaker
✔ Discussion with other participants

As of February 2021, subject to change.

Your referent

Yolanda Narain

Highly motivated and experienced project manager, with a PhD in Biological Sciences, Prince 2 Project Management certification, Team Facilitator and more than 15 years of experience in pharmacovigilance, compliance and project management. Skilled in leading and managing a wide range of national/international cross-functional projects and teams, ensuring compliance, and an appropriate stakeholder management.

Cooperation partner: College of medicine & dentistry, Birmingham (UK)

Established in 2018, we are one of the few private education providers offering a wide range of training programmes for the dental team and all healthcare professionals.  Working across a blended learning concept, we aim to reach out to all aspiring individuals to improve their knowledge and skills.  Our collaboration with Ulster University enables us to offer a wide range of career progression opportunities.

FAQ

Contact | Information material

For further information about course content, company terms or our in-house seminars please get in touch with us via email or phone. We look forward to hearing from you.

Elina Deutrich
Springer Campus Marketing
Tel.:  +49 (0) 6221 487 8428
E-mail: elina.deutrich@springernature.com

Registration | Further information about the course

Course: 

Online (live webinars) and self-directed learning

Co-operation partner: 

College of Medicine and Dentistry, Birmingham (UK) 

Duration| Workload: 

12 weeks

310 hours: 30 contact hours (live webinars), 12 hours e-learning and 268 of directed self-learning.

Level:

Level 6 degree in Pharma, Biomed, Medicine or equivalent

English test: The College of Medicine and Dentistry will do an English test (free of charge) internally to the students. The English test will be one hour maximum and will assess the applicant competencies in Speaking, Reading, Writing and Listening. The test will be focused on pharma issues. This will tick the English Language requirements for the course.

Certificate:

Certificate of the College of Medicine and Dentistry (Birmingham) with 10 ECTS

Price:

€ 2200,- (VAT-free)

Start:

Start: 15.03.2021 | Sep 2021

You can still join the course up to 4 weeks after the start date, but you will have to catch up on the material the referent studied up to that point. Simply register for the course via this page.

Booking:

For Companies:
Companies can book this course for their employees at Springer Campus:

Go to registration

For private persons:

This course can also be booked directly by private persons:

Go to registration

Customer recruits customer

You have been or are currently a participant in a Springer Campus Certificate course and know someone in your circle of friends or colleagues who might also be interested in a course? Then you are welcome to recommend us to others! For every successful placement of a participant, you will receive a customer-recruits-customer bonus of EUR 50,-.

AGB